Table 1.

Analysis of the key features of the N-glycans released from the therapeutic IgG antibodies^a

IgG	Sialylation (%)		Term. Gal (%)b	Term. GlcNAc (%)c	Bisecting GlcNAc (%)	Core fucose (%)	Predominant glycoform
	S1	S2
IVIG-Fc	16.2	2.6	62	19.2	11.4	92.8	G1F
SNA-IVIG-Fc	32.5	30.2	27.2	10.1	36.1	89.4	G2FBS1
Nivolumab	1.3	0	42.4	56.3	0	100	G0F
Bevacizumab	0	0	19	81	0	97.4	G0F
Mogamulizumab	0	0	36.3	63.7	0	0	G0

^aGlycans were quantitated by measuring peak areas in the HILIC profiles (Fig. 1)

^bGlycoforms terminating in galactose residues (G1, G1F, G1FB, G2, G2F, G2FB)

^cGlycoforms terminating in GlcNAc residues (G0 and G0F)